Skip to content

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

To keep going please Log in.

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

MGRX Mangoceuticals, Inc. Common Stock
$0.16 3.42% +0.01
Notify me if price changes either direction
Interactive Brokers Logotype

Buy MGRX stocks now with Interactive Brokers – the most advanced investment platform

Contents
  • Performance
  • Key stats
  • Financials
  • US politician trades

Mangoceuticals, Inc. Common Stock (MGRX)

Loading

Key Stats

Market cap. 3.6M
Enterprise value 3.4M
Trailing PE -0.073271886818969
PEG Ratio 0.00087010365597526
Enterprise to EBITDA -0.28
Enterprise to revenue 10.759
Price to book MRQ 0.22302158
Price to sales TTM 10.92795

Financials

Fiscal Year Ends 2025-12-31
Most Recent Quarter (MRQ) 2026-06-30
Revenue (TTM) 315.2K
EBITDA -12097073
Diluted EPS TTM -1.02
Total Cash (MRQ) 228.7K
Current ratio (MRQ) 0.176
Operating Cash Flow (TTM) -3890874

MGRX trades by the US politicians

Percentage
0% 0 sells
100% 0 buys
Amount
$0 0 sells
$0 0 buys
In the last 0 months

Recent MGRX News

Home

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.